Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting fibrosis in systemic sclerosis.

Robert Lafyatis1

  • 1Rheumatology Section, Boston University School of Medicine, Boston, MA 02118, USA. lafyatis@bu.edu

Endocrine, Metabolic & Immune Disorders Drug Targets
|January 12, 2007
PubMed
Summary

Finding effective treatments for systemic sclerosis (SSc) is challenging. Emerging therapies target the underlying immunological and fibrotic processes, including transforming growth factor-beta (TGFbeta) and interleukins (IL-4, IL-13), offering new hope for SSc patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis-Associated Lung Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Single-cell RNA sequencing of healthy and diseased rat temporomandibular joint condyle cartilage.

PloS one·2026
Same author

FOSL2 regulates endothelial cell state and chromatin accessibility in systemic sclerosis pulmonary vascular remodeling.

JCI insight·2026
Same author

SenSet defines cell-type specific senescence signatures in the aged human lung.

The EMBO journal·2026
Same author

Suppression of interferon signaling via small-molecule modulation of TFAM.

eLife·2026
Same author

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.

Annals of the rheumatic diseases·2026

Area of Science:

  • Rheumatology and Immunology
  • Translational Research
  • Fibrotic Diseases

Background:

  • Systemic sclerosis (SSc) lacks effective disease-modifying treatments.
  • Current therapies primarily manage symptoms, not the underlying pathology.
  • SSc pathogenesis involves complex interactions between vascular, immune, and connective tissues.

Purpose of the Study:

  • To review emerging therapeutics targeting SSc's core immunological and fibrotic processes.
  • To highlight key molecular pathways implicated in SSc pathogenesis.
  • To identify potential novel therapeutic targets for SSc.

Main Methods:

  • Discussion of selected emerging therapeutics and therapeutic approaches.
  • Analysis of translational research data.

Related Experiment Videos

  • Review of molecular mediators like TGFbeta, IL-4, and IL-13.

    • Main Results:

    • Transforming growth factor-beta (TGFbeta) is a central mediator in SSc fibrosis.
    • Targeting TGFbeta pathway inhibitors shows promise for SSc treatment.
    • Interleukins (IL-4, IL-13) and innate immune system modulators are potential therapeutic targets.

    Conclusions:

    • Multiple molecular targets, including TGFbeta and immune pathways, are identified for SSc therapy.
    • Development of agents targeting TGFbeta, IL-4, IL-13, and innate immunity may lead to effective SSc treatments.
    • The complexity of SSc pathogenesis offers numerous opportunities for novel therapeutic strategies.